IMMX

Immix Biopharma, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website immixbio.com
Employees(FY) 9
ISIN US45258H1068

Performance

+1.88%

+27.65%

+22.6%

+7.96%

-68.64%

YTD

-67.66%

Profile

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Advanced Technical Analysis

Technical Analysis of IMMX 2024-12-20

The Moving Average Score of 70 indicates a bullish sentiment, while the Oscillators Score of 43 suggests a neutral stance, and the overall Technical Score of 56 reflects a slightly bullish outlook. Together, these scores imply a generally positive sentiment in the stock, driven primarily by strong moving averages, despite some caution from the o...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of IMMX

Stock Rank

Recent News & Updates

2024-12-18 20:35
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis(Globenewswire)
2024-12-15 20:48
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis(Globenewswire)
2024-12-09 20:39
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024(Globenewswire)
2024-12-08 20:33
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media(Globenewswire)
2024-11-24 20:32
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients(Globenewswire)
2024-10-01 21:32
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2(Globenewswire)
2024-09-18 21:31
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board(Globenewswire)
2024-08-27 21:32
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2(Globenewswire)
2024-08-19 00:00
What Makes Immix Biopharma (IMMX) a New Buy Stock(Yahoo Finance)
2024-08-12 10:52
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024(Investorplace)
2024-07-25 09:36
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)(Globenewswire)
2024-07-07 21:31
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201(Globenewswire)
2024-06-16 21:35
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum(Globenewswire)
2024-06-09 20:30
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships(Globenewswire)
2024-05-12 21:53
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024(Investorplace)
2024-05-09 21:35
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation(Globenewswire)
2024-04-29 02:50
Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment(Yahoo Finance)
2024-04-28 21:39
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma(Globenewswire)
2024-04-17 21:37
Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States(Globenewswire)
2024-04-17 21:32
Immix Biopharma on Track to Dose NXC-201 Patients in United States(Globenewswire)
2024-04-14 21:36
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)(Globenewswire)
2024-04-01 19:53
IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023(Investorplace)
2024-03-19 21:46
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial(Globenewswire)
2024-03-04 20:35
Immix Biopharma Announces Be Proactive in AL AL Amyloidosis Awareness Initiative(Globenewswire)
2024-02-20 20:31
Immix Biopharma 12 Month Review Progress Update(Globenewswire)
2024-02-08 03:45
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock(Yahoo Finance)
2024-02-06 20:37
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis(Globenewswire)
2024-02-05 09:30
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock(Yahoo Finance)
2024-02-05 02:20
Immix Biopharma Announces Proposed Public Offering of Common Stock(Globenewswire)
2024-01-23 19:35
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.